iBio Inc (IBIO)
1.76
+0.04
(+2.33%)
USD |
NYAM |
Apr 26, 16:00
1.76
0.00 (0.00%)
After-Hours: 20:00
iBio Cash from Financing (TTM): 10.68M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 10.68M |
September 30, 2023 | 3.632M |
June 30, 2023 | 2.301M |
March 31, 2023 | -0.449M |
December 31, 2022 | -1.923M |
September 30, 2022 | -4.896M |
June 30, 2022 | -6.125M |
March 31, 2022 | -3.203M |
December 31, 2021 | 1.545M |
September 30, 2021 | 42.65M |
June 30, 2021 | 78.84M |
March 31, 2021 | 125.68M |
December 31, 2020 | 131.23M |
September 30, 2020 | 101.29M |
June 30, 2020 | 65.19M |
March 31, 2020 | 15.38M |
December 31, 2019 | 5.046M |
September 30, 2019 | 2.31M |
June 30, 2019 | 3.453M |
March 31, 2019 | 19.70M |
December 31, 2018 | 19.82M |
September 30, 2018 | 22.59M |
June 30, 2018 | 22.41M |
March 31, 2018 | 6.17M |
December 31, 2017 | 6.052M |
Date | Value |
---|---|
September 30, 2017 | 0.827M |
June 30, 2017 | -0.17M |
March 31, 2017 | 3.876M |
December 31, 2016 | 21.52M |
September 30, 2016 | 21.56M |
June 30, 2016 | 21.66M |
March 31, 2016 | 20.36M |
December 31, 2015 | 4.851M |
September 30, 2015 | 10.43M |
June 30, 2015 | 10.87M |
March 31, 2015 | 8.169M |
December 31, 2014 | 6.079M |
September 30, 2014 | 4.051M |
June 30, 2014 | 3.551M |
March 31, 2014 | 7.385M |
December 31, 2013 | 7.385M |
September 30, 2013 | 3.834M |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | 9.036M |
March 31, 2012 | 9.036M |
December 31, 2011 | 0.0447M |
September 30, 2011 | 7.366M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-6.125M
Minimum
Jun 2022
131.23M
Maximum
Dec 2020
30.14M
Average
3.632M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Lixte Biotechnology Holdings Inc | 3.143M |
PAVmed Inc | 31.17M |
Avalo Therapeutics Inc | 25.04M |
Imunon Inc | -3.639M |
Ocugen Inc | 20.88M |